The Consequence of Unnatural Selection: 160 Million Missing Girls
By Marcy Darnovsky,
Ms. Magazine Blog
| 06. 06. 2011
As best as demographers can figure, the world is short about 160 million girls and women–equivalent to the entire female population of the United States. With numbers of this magnitude in the news from time to time, many people are aware that sex selection is a matter of concern. But most Americans with whom I’ve discussed it consider sex selection somewhat abstract, and certainly faraway and fading–a practice confined to India and China, prevalent among poor people stuck in the sway of ancient traditions. The solution, they tend to assume, lies in economic development and advances in gender equality. In this view, son preference and sex selection, like the so-called population bomb of the 1960s and 1970s, will diminish more or less on their own, as a corollary of modernization and improvements in the status of women.
In the new book Unnatural Selection: Choosing Boys over Girls, and the Consequences of a World Full of Men, out this week, Beijing-based journalist Mara Hvistendahl shows these assumptions to be seriously mistaken. Selecting for sons is growing not just in South...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...